Ad/Promo: Improved Adherence Claim For Dexcel’s Hemady Not Supported, US FDA Says

 
• By Sue Sutter

A retrospective analysis does not support a claim that multiple myeloma patients are more adherent to Hemady than generic dexamethasone, OPDP said in an "untitled" letter suggesting increased enforcement focus on promotions leveraging the agency’s 2018 CFL guidance.

Excavator and trench
The FDA dug deep into the design and methodology of the study for the Hemady adherence claim. (Shutterstock)

More from Marketing & Advertising

More from R&D